A comprehensive pharmacovigilance study using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) has identified a previously unrecognized cluster of bladder-related adverse event signals associated with amifampridine. Amifampridine, a voltage-gated potassium channel blocker approved by the U.S. Food and Drug Administration in 2018 for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), works by enhancing acetylcholine release to improve neuromuscular transmission. While its safety profile has been characterized in registrational clinical trials, those studies were limited in size and follow-up duration, leaving potential long-term or rare adverse effects under-investigated in unselected real-world populations.
In this retrospective analysis, researchers examined individual case safety reports submitted to FAERS between the first quarter of 2004 and the second quarter of 2026. After applying rigorous deduplication algorithms, the study team analyzed 2,893 reports where amifampridine was identified as the primary suspect drug. To systematically detect and characterize signals, the investigators employed four complementary disproportionality algorithms: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-gamma Poisson shrinker (MGPS). This approach was designed to prioritize specificity and robustness by retaining only those adverse events that met the signal criteria of all four computational frameworks, thereby minimizing false-positive signals arising from sparse data or the unique properties of any single method.
The study results revealed that most reported signals were consistent with the well-established cholinergic toxicity of amifampridine, which is frequently associated with the medication’s therapeutic mechanism. The strongest signals were concentrated in the nervous and gastrointestinal systems, including paraesthesia oral, pharyngeal hypoaesthesia, hypoaesthesia oral, and abdominal discomfort. These findings align with earlier trial data where perioral paresthesia was reported as the most common adverse reaction. The researchers noted that these cholinergic-driven effects are typically mild to moderate in severity, though the identification of events such as dysphagia and aspiration alongside respiratory failure suggests that clinicians should maintain heightened vigilance for swallowing dysfunction during treatment, particularly in older patients.
Notably, the analysis identified a distinct cluster of bladder-related adverse events that are not included in the current prescribing information for amifampridine. These events included reports of hypertonic bladder, bladder pain, bladder spasm, and incontinence. While the researchers cautioned that autonomic dysfunction is an intrinsic pathological feature of LEMS itself—commonly manifesting as dry mouth, constipation, and urinary retention due to detrusor underactivity—the reported bladder events are directionally consistent with increased cholinergic tone, suggesting a potential detrusor overactivity phenotype. Because spontaneous reporting data cannot definitively distinguish between drug-induced effects and disease-related manifestations, the authors emphasized that this mechanistic interpretation remains explicitly hypothetical and requires validation through future prospective studies.
The temporal patterns of the reported adverse events were characterized using Weibull distribution analysis on a subset of 922 reports that provided valid information for both the drug start date and the event onset date. The study found a median time-to-onset (TTO) of 658 days, with 64.0% of events occurring more than 360 days after the initiation of treatment. The calculated shape parameter (β = 0.889, 95% CI 0.840–0.937) indicated an early-failure pattern, meaning that among the analyzed reports, the reporting rate for adverse events decreased with increasing treatment duration. The investigators cautioned that this pattern reflects the reporting dynamics within a selected subset of data and does not represent the actual temporal risk of adverse events in the general treated population.
Geographically and demographically, the study highlights the heavy reliance on data from the United States, which accounted for 98.1% of the analyzed reports. Consumer reports made up the vast majority of the data at 82.0%, reflecting the high level of participation by rare-disease patient communities in self-reporting and the accessibility of direct-to-FDA submission channels. While this richness in consumer-reported data is a valuable feature of the FAERS database, the researchers noted that it also brings inherent limitations, including a potential for less medically precise event descriptions. The sex-stratified analysis further suggested differences in reporting patterns, with males showing a higher reporting proportion for respiratory failure and gait disturbance, while gastrointestinal and cold-sensation-related events were reported more frequently by females.
The study also addressed the complexity of concomitant medication use in the LEMS population. The analysis identified heavy polypharmacy, with drugs such as pyridostigmine, vitamin D, prednisone, and various immunoglobulins frequently appearing in the patient profiles. This reflects the reality that LEMS treatment involves a combination of directed therapies, management of comorbidities, and nutritional support. Because the disproportionality framework does not adjust for the use of these co-medications, some detected signals may potentially reflect drug-drug interactions or the underlying medical management of LEMS patients. The research team identified several other context-related signals, including pulmonary mass, which is likely related to the high prevalence of small cell lung cancer in the LEMS patient population.
Acknowledging the limitations inherent in spontaneous reporting systems, the authors stated that their findings should be regarded as hypothesis-generating signals rather than definitive proof of causality. The limitations include the inability to account for underreporting, potential notoriety bias, the lack of exposure denominators, and the incomplete nature of clinical information regarding dosage, severity, and patient comorbidities. Furthermore, the exclusion of reports with invalid or missing date information restricts the TTO findings to a descriptive analysis of a specific subgroup. Despite these constraints, the study provides a comprehensive large-scale evaluation of the post-marketing safety profile of amifampridine, reinforcing the need for continuous, long-term surveillance to ensure patient safety.
In conclusion, the researchers underscore that while most identified adverse events are consistent with the known cholinergic toxicity of amifampridine, the newly identified signals related to bladder function warrant further investigation. The study provides important real-world evidence to support ongoing pharmacovigilance efforts for this rare-disease therapy. By offering a clearer understanding of the adverse events reported during long-term, real-world use, these findings can inform clinical practice and provide the necessary leads for targeted follow-up research to clarify the safety implications for LEMS patients, particularly regarding the potential for drug-induced effects in the setting of chronic, multi-drug treatment regimens.
Beyond overall signal detection, the study detailed the broad reporting foundation and clinical outcomes documented across the FAERS database. Deduplication of an initial pool of 24,812,425 individual case reports yielded 20,690,897 unique entries, from which the 2,893 primary suspect reports for amifampridine were derived. Among these records, patient outcomes included 620 hospitalizations, representing 21.4 percent of cases, and 211 deaths, accounting for 7.2 percent of reports. Additionally, disability occurred in 21 instances, while 13 cases were recorded as life-threatening, and 2,028 fell into the other outcome category. Across the 13,077 total adverse events mapped to all 27 Medical Dictionary for Regulatory Activities System Organ Classes, general disorders and administration site conditions comprised the largest share with 2,578 events, or 19.71 percent. Nervous system disorders contributed 1,885 events with a reporting odds ratio of 1.85, gastrointestinal disorders added 1,652 events with an odds ratio of 1.55, musculoskeletal and connective tissue disorders included 928 events with an odds ratio of 1.41, and infections and infestations totaled 872 events with an odds ratio of 1.28.
At the granular Preferred Term level, exactly 63 adverse events satisfied the thresholds established across all four disproportionality algorithms. The highest disproportionality point estimates appeared among cranial sensory disturbances, led by oral paraesthesia with 260 cases and a reporting odds ratio of 89.63, oral hypoaesthesia with 105 cases and an odds ratio of 33.75, pharyngeal hypoaesthesia with seven cases and an odds ratio of 36.21, and pharyngeal paraesthesia with seven cases and an odds ratio of 21.56. Neurological signals also featured general paraesthesia with 322 cases and an odds ratio of 9.99, eyelid ptosis with 19 cases and an odds ratio of 8.94, diplopia with 48 cases and an odds ratio of 8.86, and brain fog with 24 cases and an odds ratio of 7.89. In the newly detected bladder symptom cluster, 26 total event records came from 22 separate patient reports, consisting of hypertonic bladder with seven cases and an odds ratio of 11.64, bladder pain with four cases and an odds ratio of 6.06, bladder spasm with three cases and an odds ratio of 7.71, and non-specific incontinence with 12 cases and an odds ratio of 5.41.
To address potential reporting bias from direct consumer submissions, a sensitivity analysis evaluated the subgroup of 158 reports filed by healthcare professionals, comprising 859 event records. Within this professional subset, 16 Preferred Terms fulfilled all four algorithmic benchmarks. Known signals remained robust, including oral paraesthesia with a reporting odds ratio of 47.81 and asthenia with an odds ratio of 5.65, while acute respiratory failure emerged with a prominent odds ratio of 16.34. Furthermore, the methodological breakdown of the time-to-onset analysis showed that from the initial 2,893 reports, 1,305 lacked requisite start or onset dates, 46 contained unparseable entries, 451 yielded negative intervals, and 167 produced zero-day intervals. This left 922 valid cases for Weibull modeling, where the estimated scale parameter reached 829.0 days, and 82 adverse events occurred within the first 30 days of therapy.
Subject of Research: Systematic post-marketing pharmacovigilance analysis of amifampridine safety profile using the FAERS database.
Article Title: Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database
Article References: Yang, C., & Wang, C. (2026). Safety profile of amifampridine in real-world use: a disproportionality analysis of the FAERS database. Frontiers in Pharmacology, 17, Article 2013910. https://doi.org/10.3389/fphar.2026.2013910
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.2013910
Keywords: Amifampridine, Pharmacovigilance, Lambert-Eaton myasthenic syndrome, FAERS, Adverse drug events, Disproportionality analysis, Cholinergic toxicity, Hypertonic bladder, Drug safety, Real-world evidence, Neurological disorders, LEMS treatment, Spontaneous reporting, MedDRA, Post-marketing surveillance

